PH12019502380A1 - Compositions and methods for treating retinopathy - Google Patents
Compositions and methods for treating retinopathyInfo
- Publication number
- PH12019502380A1 PH12019502380A1 PH12019502380A PH12019502380A PH12019502380A1 PH 12019502380 A1 PH12019502380 A1 PH 12019502380A1 PH 12019502380 A PH12019502380 A PH 12019502380A PH 12019502380 A PH12019502380 A PH 12019502380A PH 12019502380 A1 PH12019502380 A1 PH 12019502380A1
- Authority
- PH
- Philippines
- Prior art keywords
- compositions
- methods
- treating retinopathy
- retinopathy
- treating
- Prior art date
Links
- 208000017442 Retinal disease Diseases 0.000 title abstract 2
- 206010038923 Retinopathy Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762488161P | 2017-04-21 | 2017-04-21 | |
| PCT/US2018/028552 WO2018195411A1 (en) | 2017-04-21 | 2018-04-20 | Compositions and methods for treating retinopathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12019502380A1 true PH12019502380A1 (en) | 2020-09-14 |
Family
ID=62117055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12019502380A PH12019502380A1 (en) | 2017-04-21 | 2019-10-21 | Compositions and methods for treating retinopathy |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11351136B2 (https=) |
| EP (1) | EP3612225A1 (https=) |
| JP (1) | JP7171611B2 (https=) |
| KR (1) | KR20190138683A (https=) |
| CN (1) | CN110769855A (https=) |
| AU (1) | AU2018254556B2 (https=) |
| CA (1) | CA3060417A1 (https=) |
| EA (1) | EA201992515A1 (https=) |
| MX (1) | MX2019012476A (https=) |
| PH (1) | PH12019502380A1 (https=) |
| WO (1) | WO2018195411A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12021552866A1 (en) | 2019-05-14 | 2022-11-07 | Tyme Inc | Compositions and methods for treating cancer |
| US10905698B1 (en) | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0451422A1 (en) * | 1990-04-13 | 1991-10-16 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutically active fluoromethyltyrosine compounds |
| DE60023926T2 (de) * | 1999-09-10 | 2006-07-20 | Merck & Co., Inc. | Tyrosin kinase inhibitoren |
| CN1245966C (zh) | 1999-11-30 | 2006-03-22 | 爱尔康公司 | β－肾上腺素受体拮抗剂用于制备治疗外层视网膜疾病的药物的用途 |
| EP1337272A2 (en) | 2000-11-30 | 2003-08-27 | Pfizer Products Inc. | Combination of gaba agonists and aldose reductase inhibitors |
| NZ552816A (en) | 2007-01-24 | 2009-05-31 | Bomac Research Ltd | Formulation for transdermal administration of antihyperthyroid drug comprising a penetration enhancer selected from oleic acid, d-limonene, pyrrolidones, a C2-C8 alcohol, glycol ethers, triacetin and combinations thereof |
| CA2680843C (en) | 2007-01-29 | 2016-05-31 | Vlife Sciences Technologies Pvt. Ltd. | Pharmaceutical composition for treatment of diabetic complications |
| AU2008347005B2 (en) | 2008-01-03 | 2013-10-03 | Biomarin Pharmaceutical Inc. | Pterin analog for treating BH4 responsive condition |
| US20100204325A1 (en) | 2009-02-11 | 2010-08-12 | Allergan, Inc. | Valproic acid drug delivery systems and intraocular therapeutic uses thereof |
| PL2804599T3 (pl) * | 2012-01-17 | 2019-06-28 | Tyme, Inc. | Terapia skojarzona do leczenia nowotworu złośliwego |
| US9962362B2 (en) * | 2012-03-29 | 2018-05-08 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting EYA tyrosine phosphatase |
| US9585841B2 (en) * | 2013-10-22 | 2017-03-07 | Tyme, Inc. | Tyrosine derivatives and compositions comprising them |
| US20150111878A1 (en) * | 2013-10-22 | 2015-04-23 | Steven Hoffman | Compositions and methods for treating intestinal hyperpermeability |
| MX2017008423A (es) | 2014-12-23 | 2017-10-26 | Hoffman Steven | Formulaciones transdérmicas. |
| US9687528B2 (en) | 2014-12-23 | 2017-06-27 | Steven Hoffman | Transdermal formulations |
-
2018
- 2018-04-20 CN CN201880034705.1A patent/CN110769855A/zh active Pending
- 2018-04-20 WO PCT/US2018/028552 patent/WO2018195411A1/en not_active Ceased
- 2018-04-20 EA EA201992515A patent/EA201992515A1/ru unknown
- 2018-04-20 KR KR1020197033914A patent/KR20190138683A/ko not_active Withdrawn
- 2018-04-20 CA CA3060417A patent/CA3060417A1/en not_active Abandoned
- 2018-04-20 JP JP2019557486A patent/JP7171611B2/ja active Active
- 2018-04-20 MX MX2019012476A patent/MX2019012476A/es unknown
- 2018-04-20 EP EP18723209.5A patent/EP3612225A1/en active Pending
- 2018-04-20 AU AU2018254556A patent/AU2018254556B2/en active Active
- 2018-04-20 US US15/958,598 patent/US11351136B2/en active Active
-
2019
- 2019-10-21 PH PH12019502380A patent/PH12019502380A1/en unknown
-
2022
- 2022-06-02 US US17/830,458 patent/US12364676B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018195411A1 (en) | 2018-10-25 |
| EA201992515A1 (ru) | 2020-04-09 |
| US12364676B2 (en) | 2025-07-22 |
| EP3612225A1 (en) | 2020-02-26 |
| US20180303783A1 (en) | 2018-10-25 |
| JP7171611B2 (ja) | 2022-11-15 |
| AU2018254556A1 (en) | 2019-11-14 |
| MX2019012476A (es) | 2020-02-12 |
| US11351136B2 (en) | 2022-06-07 |
| US20220288003A1 (en) | 2022-09-15 |
| KR20190138683A (ko) | 2019-12-13 |
| CA3060417A1 (en) | 2018-10-25 |
| AU2018254556B2 (en) | 2024-05-02 |
| CN110769855A (zh) | 2020-02-07 |
| JP2020517663A (ja) | 2020-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ795278A (en) | Antibody-pyrrolobenzodiazepine derivative conjugate | |
| MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
| MX2021006235A (es) | Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos. | |
| MX2019007021A (es) | Anticuerpos il-11ra. | |
| MX392368B (es) | Composiciones y metodos para el tratamiento del cancer | |
| MX2017005260A (es) | Bifidobacterias activadas y metodos de uso de las mismas. | |
| PH12017501780A1 (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| MX2019007020A (es) | Anticuerpos il-11. | |
| EP4193993A3 (en) | Combinations of cannabinoids and n-acylethanolamines | |
| PH12016502142B1 (en) | Anti-ptk7 antibody-drug conjugates | |
| PH12018500887A1 (en) | Anti-htra1 antibodies and methods of use thereof | |
| SG10201906471PA (en) | Treatment of cancer with anti-lap monoclonal antibodies | |
| EP4385521A3 (en) | Storage stable compositions and methods for the treatment of refractive errors of the eye | |
| ZA201907028B (en) | Fabric care composition | |
| HK1217490A1 (zh) | 黃斑變性治療中的新穎捕獲劑 | |
| MX2019000088A (es) | Composiciones y metodos para detectar y tratar la diabetes. | |
| MY186271A (en) | Ophthalmic compositions and methods of use therefor | |
| WO2018009507A8 (en) | COMBINATION OF A TIM -4 ANTAGONIST AND METHODS OF USE | |
| MX2019006576A (es) | Metodos y materiales para usar soportes de fibrina para trasplante de epitelio de pigmento retiniano. | |
| ZA201905895B (en) | Kits and methods for preparing pathogen-inactivated platelet compositions | |
| WO2019086646A8 (en) | Feline leukemia virus vaccine | |
| PH12017501864A1 (en) | Compositions and methods for treating autism | |
| JOP20190164B1 (ar) | تركيبات وطرق لعلاج داء فاربر | |
| MX2019006551A (es) | Terapia génica para mucopolisacaridosis de tipo ii. | |
| AU2016361427A8 (en) | Platinum anticancer agents |